Jefferies Group LLC Aurinia Pharmaceuticals Inc. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.66 - $12.39 $322,763 - $600,456	48,463 New	48,463 $2,000
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $190,545 - $272,512	-21,290 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$10.05 - $22.48 $168,237 - $376,315	16,740 Added 367.91%	21,290 $16,000
Q4 2021 Sep 21, 2023	BUY	$17.78 - $33.08 $79,121 - $147,206	4,450 Added 4450.0%	4,550 $104,000
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $79,121 - $147,206	4,450 Added 4450.0%	4,550 $104,000
Q3 2021 Sep 21, 2023	SELL	$10.93 - $23.55 $528,607 - $1.14 Million	-48,363 Reduced 99.79%	100 $2,000
Q3 2021 Nov 15, 2021	SELL	$10.93 - $23.55 $64,487 - $138,945	-5,900 Reduced 98.33%	100 $2,000
Q4 2019 Feb 13, 2020	BUY	$3.88 - $21.42 $23,280 - $128,520	6,000 New	6,000 $122,000

210

58.2M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.1B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.